![PDF) Prospective multicentre randomized double-blind placebo-controlled parallel group study on the efficacy and tolerability of StroVac® in patients with recurrent symptomatic uncomplicated bacterial urinary tract infections PDF) Prospective multicentre randomized double-blind placebo-controlled parallel group study on the efficacy and tolerability of StroVac® in patients with recurrent symptomatic uncomplicated bacterial urinary tract infections](https://i1.rgstatic.net/publication/364091487_Prospective_multicentre_randomized_double-blind_placebo-controlled_parallel_group_study_on_the_efficacy_and_tolerability_of_StroVacR_in_patients_with_recurrent_symptomatic_uncomplicated_bacterial_urin/links/6338f1769cb4fe44f3f3cef9/largepreview.png)
PDF) Prospective multicentre randomized double-blind placebo-controlled parallel group study on the efficacy and tolerability of StroVac® in patients with recurrent symptomatic uncomplicated bacterial urinary tract infections
![Frontiers | A suspension of inactivated bacteria used for vaccination against recurrent urinary tract infections increases the phagocytic activity of murine macrophages Frontiers | A suspension of inactivated bacteria used for vaccination against recurrent urinary tract infections increases the phagocytic activity of murine macrophages](https://www.frontiersin.org/files/Articles/1180785/fimmu-14-1180785-HTML/image_m/fimmu-14-1180785-g004.jpg)
Frontiers | A suspension of inactivated bacteria used for vaccination against recurrent urinary tract infections increases the phagocytic activity of murine macrophages
![Frontiers | A suspension of inactivated bacteria used for vaccination against recurrent urinary tract infections increases the phagocytic activity of murine macrophages Frontiers | A suspension of inactivated bacteria used for vaccination against recurrent urinary tract infections increases the phagocytic activity of murine macrophages](https://www.frontiersin.org/files/Articles/1180785/fimmu-14-1180785-HTML/image_m/fimmu-14-1180785-g001.jpg)